Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab.
Tomokazu KawaokaYuwa AndoMasami YamauchiYosuke SuehiroKenji YamaokaYumi KosakaYasutomo FujiShinsuke UchikawaKei MorioHatsue FujinoTakashi NakaharaAtsushi OnoEisuke MurakamiShoichi TakahashiMasataka TsugeAkira HiramatsuMichio ImamuraKazuaki ChayamaHiroshi AikataPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2020)
MSI-H tumor status was found in only two of 82 (2.4%) Japanese patients with advanced HCC, one of whom had a complete response to pembrolizumab. Thus, MSI status should be assessed in patients with HCC who progress after standard of care treatment.